CD39 inhibitor (POM-1) enhances radiosensitivity of esophageal squamous cell carcinoma (ESCC) cells by promoting apoptosis through the Bax/Bcl-2/Caspase 9/Caspase 3 pathway
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.113242 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Yuchen Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Apoptosis, Esophageal Squamous Cell Carcinoma, Radiation Tolerance. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
CD39 inhibitor (sodium polyoxotungstate, POM-1) has been reported to have antitumor effects. However, the synergistic effect of POM-1 with radiotherapy requires further elucidation. This study aimed to investigate the role and the molecular mechanism of POM-1 in esophageal squamous cell carcinoma (ESCC) radiosensitization. Firstly, the expression of CD39 in ESCC cells and normal esophageal epithelial cells were detected. Then radioresistant ESCC cells (Eca109R and KYSE150R) were constructed and CD39 expression was analyzed. Furthermore, the effect of POM-1 on radiosensitivity for parent cells and radioresistant cells were observed. Then, we analyzed the effect of POM-1 and CD39 siRNA on radiotherapy-induced apoptosis and determined whether POM-1 modulated the radioresistance of ESCC cells depending on the apoptotic signaling pathway. Finally, we validated the synergistic effect of POM-1 combined with radiotherapy in vivo. Our results showed that CD39 was highly expressed in ESCC cells and radioresistant ESCC cells (p < 0.05). POM-1 reduced radioresistance and proliferation of parent cells and radioresistant cells (p < 0.05). Further mechanistic exploration showed that inhibition of CD39 promoted radiation-induced apoptosis (p < 0.05). Bax knockdown reversed the effect of POM-1 on ESCC cells (p < 0.01). Animal experiments also validated that radiotherapy combined with POM-1 enhanced tumor inhibition in vivo (p < 0.05). These results suggested that POM-1 had synergistic effect with radiotherapy by enhancing cell apoptosis through Bax/Bcl-2 signal pathway in ESCC. The combination of POM-1 and radiotherapy is expected to enhance the anti-tumor effect in ESCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- The Comprehensive Breast Care Center, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Electronic address: qujingkun@xjtu.edu.cn.
- Department of Radiation Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Electronic address: mhbxian@126.com.
- Department of Radiation Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Electronic address: xixizhao@xjtu.edu.cn.
Zitieren
APA
Wang, Y., Zhang, R., Huang, X., He, X., Geng, S., Pan, S., Guo, W., Liu, X., Dang, Y., Qu, J., Ma, H., & Zhao, X. (2024). CD39 inhibitor (POM-1) enhances radiosensitivity of esophageal squamous cell carcinoma (ESCC) cells by promoting apoptosis through the Bax/Bcl-2/Caspase 9/Caspase 3 pathway. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113242
Vancouver
Wang Y, Zhang R, Huang X, He X, Geng S, Pan S, et al. CD39 inhibitor (POM-1) enhances radiosensitivity of esophageal squamous cell carcinoma (ESCC) cells by promoting apoptosis through the Bax/Bcl-2/Caspase 9/Caspase 3 pathway. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.113242
BibTeX
@article{Wang2024,
author = {Wang, Yuchen and Zhang, Ruijuan and Huang, Xinran and He, Xinyu and Geng, Shangyi and Pan, Shupei and Guo, Wei and Liu, Xiaoxiao and Dang, Yongze and Qu, Jingkun and Ma, Hongbing and Zhao, Xixi},
title = {CD39 inhibitor (POM-1) enhances radiosensitivity of esophageal squamous cell carcinoma (ESCC) cells by promoting apoptosis through the Bax/Bcl-2/Caspase 9/Caspase 3 pathway},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.113242}
}
EUVIMED